对侧预防性乳房切除术时隐匿性恶性肿瘤和前哨淋巴结转移的系统回顾。

IF 3.5 2区 医学 Q2 ONCOLOGY
Jenna L Sturz-Ellis, Christopher D Vetter, Courtney N Day, Judy C Boughey
{"title":"对侧预防性乳房切除术时隐匿性恶性肿瘤和前哨淋巴结转移的系统回顾。","authors":"Jenna L Sturz-Ellis, Christopher D Vetter, Courtney N Day, Judy C Boughey","doi":"10.1245/s10434-025-18474-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Occult malignancy (OM) identified in contralateral prophylactic mastectomy (CPM) presents a challenge for axillary management.</p><p><strong>Methods: </strong>This meta-analysis identified retrospective studies using PubMed, Embase, and Cochrane Reviews with the keywords OM and CPM. In this study, OM was defined as invasive disease only. To determine the proportion of OM and node positivity rates, MedCalc software was used.</p><p><strong>Results: </strong>The 27 studies in this meta-analysis included 5728 patients who underwent CPM, with OM identified in 87 patients. The pooled incidence of OM was 1.55%. Of the 73 patients with axillary staging details available, 41 patients with OM (56%) underwent surgical axillary staging. Of these 41 patients, 8 had a positive sentinel lymph node (SLN) (20%), and 4 of the 8 patients had subsequent axillary lymph node dissection (ALND) with no additional positive lymph nodes identified. For 64 of the 87 patients with OM, T category was available. Of these 64 patients, 62 (97%) had pT1 and 2 (3%) had pT2 carcinoma. Histologic subtype was available for 52 OMs. Of these, 39 (75%) were ductal, 8 (15%) were lobular, and 5 (10%) were other. Biomarkers were available for 33 OMs, of which 21 (64%) were luminal A, 3 (9%) were luminal B, 3 (9%) were luminal human epidermal growth factor receptor 2 (HER2), and 6 (18%) were triple-negative.</p><p><strong>Conclusions: </strong>Occult malignancy in CPM is uncommon (1.55%), and when it occurs, it is predominantly pT1, luminal A, or invasive ductal carcinoma. Occult malignancy with SLN metastasis occurs in only 0.1% of CPMs, and when present, SLN metastasis is low volume (≤2 nodes). This supports the current guideline recommendations against routine SLN surgery at the time of CPM.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Systematic Review of Occult Malignancy and Sentinel Lymph Node Metastasis at the Time of Contralateral Prophylactic Mastectomy.\",\"authors\":\"Jenna L Sturz-Ellis, Christopher D Vetter, Courtney N Day, Judy C Boughey\",\"doi\":\"10.1245/s10434-025-18474-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Occult malignancy (OM) identified in contralateral prophylactic mastectomy (CPM) presents a challenge for axillary management.</p><p><strong>Methods: </strong>This meta-analysis identified retrospective studies using PubMed, Embase, and Cochrane Reviews with the keywords OM and CPM. In this study, OM was defined as invasive disease only. To determine the proportion of OM and node positivity rates, MedCalc software was used.</p><p><strong>Results: </strong>The 27 studies in this meta-analysis included 5728 patients who underwent CPM, with OM identified in 87 patients. The pooled incidence of OM was 1.55%. Of the 73 patients with axillary staging details available, 41 patients with OM (56%) underwent surgical axillary staging. Of these 41 patients, 8 had a positive sentinel lymph node (SLN) (20%), and 4 of the 8 patients had subsequent axillary lymph node dissection (ALND) with no additional positive lymph nodes identified. For 64 of the 87 patients with OM, T category was available. Of these 64 patients, 62 (97%) had pT1 and 2 (3%) had pT2 carcinoma. Histologic subtype was available for 52 OMs. Of these, 39 (75%) were ductal, 8 (15%) were lobular, and 5 (10%) were other. Biomarkers were available for 33 OMs, of which 21 (64%) were luminal A, 3 (9%) were luminal B, 3 (9%) were luminal human epidermal growth factor receptor 2 (HER2), and 6 (18%) were triple-negative.</p><p><strong>Conclusions: </strong>Occult malignancy in CPM is uncommon (1.55%), and when it occurs, it is predominantly pT1, luminal A, or invasive ductal carcinoma. Occult malignancy with SLN metastasis occurs in only 0.1% of CPMs, and when present, SLN metastasis is low volume (≤2 nodes). This supports the current guideline recommendations against routine SLN surgery at the time of CPM.</p>\",\"PeriodicalId\":8229,\"journal\":{\"name\":\"Annals of Surgical Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Surgical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1245/s10434-025-18474-4\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1245/s10434-025-18474-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:对侧预防性乳房切除术(CPM)中发现的隐匿性恶性肿瘤(OM)对腋窝治疗提出了挑战。方法:本荟萃分析采用PubMed、Embase和Cochrane综述,以OM和CPM为关键词进行回顾性研究。在本研究中,OM仅被定义为侵袭性疾病。采用MedCalc软件测定OM阳性率和淋巴结阳性率的比例。结果:本荟萃分析的27项研究包括5728例接受CPM的患者,其中87例确诊为OM。OM的合并发病率为1.55%。在73例可获得腋窝分期细节的患者中,41例OM患者(56%)接受了手术腋窝分期。在这41例患者中,8例前哨淋巴结(SLN)阳性(20%),8例患者中有4例随后进行了腋窝淋巴结清扫(ALND),未发现其他阳性淋巴结。87例OM患者中64例为T型。在这64例患者中,62例(97%)为pT1, 2例(3%)为pT2癌。52例OMs有组织学亚型。其中,导管39例(75%),小叶8例(15%),其他5例(10%)。33个OMs可获得生物标志物,其中21个(64%)为管腔A, 3个(9%)为管腔B, 3个(9%)为管腔人表皮生长因子受体2 (HER2), 6个(18%)为三阴性。结论:隐匿性恶性肿瘤在CPM中并不常见(1.55%),当它发生时,主要是pT1,管腔A或浸润性导管癌。伴有SLN转移的隐匿性恶性肿瘤仅占cpm的0.1%,即使存在,SLN转移也是小体积的(≤2个淋巴结)。这支持了目前的指南建议,反对在CPM时进行常规SLN手术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Systematic Review of Occult Malignancy and Sentinel Lymph Node Metastasis at the Time of Contralateral Prophylactic Mastectomy.

Background: Occult malignancy (OM) identified in contralateral prophylactic mastectomy (CPM) presents a challenge for axillary management.

Methods: This meta-analysis identified retrospective studies using PubMed, Embase, and Cochrane Reviews with the keywords OM and CPM. In this study, OM was defined as invasive disease only. To determine the proportion of OM and node positivity rates, MedCalc software was used.

Results: The 27 studies in this meta-analysis included 5728 patients who underwent CPM, with OM identified in 87 patients. The pooled incidence of OM was 1.55%. Of the 73 patients with axillary staging details available, 41 patients with OM (56%) underwent surgical axillary staging. Of these 41 patients, 8 had a positive sentinel lymph node (SLN) (20%), and 4 of the 8 patients had subsequent axillary lymph node dissection (ALND) with no additional positive lymph nodes identified. For 64 of the 87 patients with OM, T category was available. Of these 64 patients, 62 (97%) had pT1 and 2 (3%) had pT2 carcinoma. Histologic subtype was available for 52 OMs. Of these, 39 (75%) were ductal, 8 (15%) were lobular, and 5 (10%) were other. Biomarkers were available for 33 OMs, of which 21 (64%) were luminal A, 3 (9%) were luminal B, 3 (9%) were luminal human epidermal growth factor receptor 2 (HER2), and 6 (18%) were triple-negative.

Conclusions: Occult malignancy in CPM is uncommon (1.55%), and when it occurs, it is predominantly pT1, luminal A, or invasive ductal carcinoma. Occult malignancy with SLN metastasis occurs in only 0.1% of CPMs, and when present, SLN metastasis is low volume (≤2 nodes). This supports the current guideline recommendations against routine SLN surgery at the time of CPM.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.90
自引率
10.80%
发文量
1698
审稿时长
2.8 months
期刊介绍: The Annals of Surgical Oncology is the official journal of The Society of Surgical Oncology and is published for the Society by Springer. The Annals publishes original and educational manuscripts about oncology for surgeons from all specialities in academic and community settings.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信